Three biotechs price hefty IPOs just before the weekend, while a fourth and a SPAC seek spots on Wall Street
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
A handful of biotechs are hitting Wall Street …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
